Logo image of TRIB

TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Fundamental Analysis

NASDAQ:TRIB - Nasdaq - US8964385046 - ADR - Currency: USD

0.85  +0.06 (+6.99%)

After market: 0.8 -0.05 (-5.88%)

Fundamental Rating

1

Taking everything into account, TRIB scores 1 out of 10 in our fundamental rating. TRIB was compared to 190 industry peers in the Health Care Equipment & Supplies industry. TRIB may be in some trouble as it scores bad on both profitability and health. TRIB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TRIB had negative earnings in the past year.
In the past year TRIB has reported a negative cash flow from operations.
TRIB had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.
TRIB Yearly Net Income VS EBIT VS OCF VS FCFTRIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

TRIB has a Return On Assets of -20.87%. This is comparable to the rest of the industry: TRIB outperforms 51.85% of its industry peers.
Industry RankSector Rank
ROA -20.87%
ROE N/A
ROIC N/A
ROA(3y)-28.07%
ROA(5y)-22.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIB Yearly ROA, ROE, ROICTRIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K 1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 35.74%, TRIB is doing worse than 70.90% of the companies in the same industry.
In the last couple of years the Gross Margin of TRIB has declined.
TRIB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.44%
GM growth 5Y-4.34%
TRIB Yearly Profit, Operating, Gross MarginsTRIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
TRIB has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, TRIB has more shares outstanding
TRIB has a worse debt/assets ratio than last year.
TRIB Yearly Shares OutstandingTRIB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
TRIB Yearly Total Debt VS Total AssetsTRIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

TRIB has an Altman-Z score of -0.42. This is a bad value and indicates that TRIB is not financially healthy and even has some risk of bankruptcy.
TRIB has a Altman-Z score (-0.42) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.42
ROIC/WACCN/A
WACC9.77%
TRIB Yearly LT Debt VS Equity VS FCFTRIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

TRIB has a Current Ratio of 1.64. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
TRIB has a worse Current ratio (1.64) than 73.02% of its industry peers.
TRIB has a Quick Ratio of 1.64. This is a bad value and indicates that TRIB is not financially healthy enough and could expect problems in meeting its short term obligations.
TRIB has a Quick ratio of 0.87. This is amonst the worse of the industry: TRIB underperforms 83.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 0.87
TRIB Yearly Current Assets VS Current LiabilitesTRIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.11% over the past year.
The Revenue has decreased by -0.01% in the past year.
TRIB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.15% yearly.
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.75%
Revenue 1Y (TTM)-0.01%
Revenue growth 3Y-17.71%
Revenue growth 5Y-10.15%
Sales Q2Q%3.24%

3.2 Future

The Earnings Per Share is expected to grow by 5.36% on average over the next years.
TRIB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.95% yearly.
EPS Next Y-194.92%
EPS Next 2Y-23.51%
EPS Next 3Y5.36%
EPS Next 5YN/A
Revenue Next Year6.69%
Revenue Next 2Y8.4%
Revenue Next 3Y9.95%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TRIB Yearly Revenue VS EstimatesTRIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
TRIB Yearly EPS VS EstimatesTRIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRIB. In the last year negative earnings were reported.
Also next year TRIB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIB Price Earnings VS Forward Price EarningsTRIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRIB Per share dataTRIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.51%
EPS Next 3Y5.36%

More info and screens

0

5. Dividend

5.1 Amount

TRIB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (5/2/2025, 8:26:13 PM)

After market: 0.8 -0.05 (-5.88%)

0.85

+0.06 (+6.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)05-22 2025-05-22/bmo
Inst Owners4.63%
Inst Owner Change-0.44%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.31M
Analysts85.71
Price TargetN/A
Short Float %2.82%
Short Ratio1.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.4%
Min EPS beat(2)-7.69%
Max EPS beat(2)16.49%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.68%
Min Revenue beat(2)-9.97%
Max Revenue beat(2)-1.38%
Revenue beat(4)0
Avg Revenue beat(4)-8.38%
Min Revenue beat(4)-12.24%
Max Revenue beat(4)-1.38%
Revenue beat(8)1
Avg Revenue beat(8)-8.64%
Revenue beat(12)1
Avg Revenue beat(12)-16.66%
Revenue beat(16)4
Avg Revenue beat(16)-11.95%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS3.08
BVpS-1.37
TBVpS-3.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.74%
FCFM N/A
ROA(3y)-28.07%
ROA(5y)-22.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.44%
GM growth 5Y-4.34%
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 431.9%
Cap/Sales 13.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 0.87
Altman-Z -0.42
F-Score4
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)241.7%
Cap/Depr(5y)259.74%
Cap/Sales(3y)8.34%
Cap/Sales(5y)9.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.75%
EPS Next Y-194.92%
EPS Next 2Y-23.51%
EPS Next 3Y5.36%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.01%
Revenue growth 3Y-17.71%
Revenue growth 5Y-10.15%
Sales Q2Q%3.24%
Revenue Next Year6.69%
Revenue Next 2Y8.4%
Revenue Next 3Y9.95%
Revenue Next 5YN/A
EBIT growth 1Y27.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-256.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-357.13%
OCF growth 3YN/A
OCF growth 5YN/A